| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 31st December 2020 | David G Foster | 11,052 | Open or private sale | $6.38 | $70,511.76 |
| 31st December 2020 | Anna Berkenblit | 2,203 | Grant/award etc. | $4.04 | $8,900.12 |
| 31st December 2020 | David G Foster | 362 | Grant/award etc. | $4.04 | $1,462.48 |
| 31st December 2020 | David G Foster | 27,240 | Exercise of derivative | $0.00 | |
| 31st December 2020 | Theresa Wingrove | 2,659 | Grant/award etc. | $4.04 | $10,742.36 |
| 1st July 2020 | David G Foster | 342 | Grant/award etc. | $3.91 | $1,337.22 |
| 30th June 2020 | Anna Berkenblit | 3,047 | Grant/award etc. | $3.91 | $11,913.77 |
| 30th June 2020 | Mark J Enyedy | 5,241 | Grant/award etc. | $3.91 | $20,492.31 |
| 30th June 2020 | Thomas Ryll | 5,241 | Grant/award etc. | $3.91 | $20,492.31 |
| 30th June 2020 | Theresa Wingrove | 2,593 | Grant/award etc. | $3.91 | $10,138.63 |
Immuno Gen
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
ImmunoGen, Inc. was founded in March 1981 and is headquartered in Waltham, MA. Its product candidates include Mirvetuximab soravtansine, Coltuximbe ravtansin, IMGN7779 and IMGN632.
Ticker: IMGN
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 855654
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $699 Th for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $2 M for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $19 M for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $20 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $220 M (0%)
Assets, Current: $241 M (15%)
Property, Plant and Equipment, Net: $6 M (-15%)
Other Assets, Noncurrent: $8 M (100%)
Assets: $270 M (14%)
Accounts Payable, Current: $13 M (28%)
Liabilities, Current: $91 M (17%)
Other Liabilities, Noncurrent: $3 M (265%)
Liabilities: $294 M (-5%)
Common Stock, Value, Issued: $2 M (16%)
Common Stock, Shares, Issued: $175 Th (-99%)
Additional Paid in Capital, Common Stock: $1 B (8%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Stockholders' Equity (Parent): $25 M (0%)
Liabilities and Equity: $270 M (14%)
Research and Development: $23 M (-54%)
General and Administrative Expenses: $10 M (-47%)
Restructuring Charges: $699 Th (-54%)
Operating Income/Loss: $18 M (-56%)
News
ImmunoGen: Major Catalysts This Year
24th February 2021
ImmunoGen: Update On A Turnaround Story
9th December 2020